FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1007-1008 October 1, 1998 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Bert Vogelstein and Kenneth W. Kinzler. 731 pp., illustrated. New York, McGraw-Hill, 1998. $95. ISBN 0-07-067596-1.

During the past two decades, our knowledge of the pathogenesis of cancer has progressed from the unidimensional notion of cancer-causing, dominant mutations that accelerate growth (oncogenes) to a complex picture involving growth inhibition (tumor suppressors, or gatekeepers), programmed cell death (apoptosis genes), and more recently, elements that control the stability of DNA and chromosomes (caretakers). With each of these discoveries has come the opportunity for improved diagnosis and prognosis. Furthermore, the first generation of therapeutic products based on these insights is now entering clinical trials. Our understanding is at such a level of sophistication that for patients with a genetic . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.